Company intelligence / Profile preview

Amniotics

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

Amniotics has completed GMP process validation and entered clinical phase with its lead candidate PulmoStem™, a first-in-class cell therapy targeting severe pulmonary disease. The company’s unique approach leverages neonatal-quality MSCs derived from full-term amniotic fluid. Early-stage results focus on safety and feasibility; efficacy data pending as trials progress. Additional candidates are in preclinical development across multiple organ systems.

Therapeutic areas: PulmonologyOther
Modalities: Stem cell therapyCell therapyAdvanced Therapy Medicinal ProductBiologic
Industry: Biotech

Partnerships

Strategic partnerships sought with researchers/universities/hospitals/pharma companies interested in ATMP development; no major pharma partnership publicly disclosed yet

Beyond the preview

Go deeper on Amniotics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amniotics.

Explore the full profile